Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

GSK and CureVac secure $740m payout in mRNA patent settlement

Fri 08 Aug 2025 07:36

(Sharecast News) - Drugmaker GSK said on Friday that it had reached a settlement, alongside CureVac, to resolve long-running patent litigation with BioNTech and Pfizer over mRNA-based COVID-19 vaccines. The agreement, which includes a substantial upfront payment of $370m and future royalties, marks a significant step in monetising GSK's intellectual property portfolio.

Under the terms of the deal, CureVac and GSK will receive a combined $740m from BioNTech and Pfizer, along with single-digit royalties on future US sales of Covid-19 vaccines. CureVac will also receive an additional $50m from GSK for monetising part of its royalty stream under an existing licensing agreement.

GSK highlighted that the settlement includes a non-exclusive licence for BioNTech and Pfizer to manufacture and sell mRNA-based Covid-19 and influenza products in the US, which will expand globally following the completion of BioNTech's acquisition of CureVac.

GSK added that all pending litigation in the US has been dismissed, with a framework in place to resolve disputes elsewhere.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Thu 15 Oct 2026 13:51
Culture Secretary 'minded to intervene' in Sky-ITV deal
(Sharecast News) - Culture secretary Lisa Nandy on Thursday revealed that she is "minded to intervene" in Sky's proposed takeover of ITV's media and entertainment activities, suggesting possible legislation of the streaming industry may be needed.
Thu 15 Oct 2026 13:49
AstraZeneca enters into strategic drug discovery deal with AI biotech Insitro
(Sharecast News) - AstraZeneca said on Thursday that it will pay up to $1.86bn to enter a new strategic drug discovery collaboration and licensing agreement with Califiornia-based AI biotech firm Insitro.
Thu 15 Oct 2026 12:08
Berenberg lifts target price on Discoverie following H1 update
(Sharecast News) - Analysts at Berenberg lifted their target price for DiscoverIE from 1,050p to 1,100p on Thursday, citing sustained organic momentum, a strengthening order book and earnings running ahead of expectations.
Thu 15 Oct 2026 12:02
Friday preview: Man Group update, eurozone inflation eyed
(Sharecast News) - Friday will mark a fairly quiet end to a busy week that saw the release of a slew of US bank earnings.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statements | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026